# Phenotypes, Biomarkers and Pathophysiology in Spastic Ataxias

> **NCT04297891** · — · UNKNOWN · sponsor: **Dr. Rebecca Schule** · enrollment: 250 (estimated)

## Conditions studied

- Spastic Ataxia

## Interventions

- **OTHER:** Clinical rating scale to measure Ataxia disease severity and progression
- **OTHER:** Clinical rating scale to measure spastic paraplegia disease severity and progression
- **OTHER:** Disease-specific severity index for adults with autosomal recessive spastic ataxia of Charlevoix-Saguenay (ARSACS)
- **DIAGNOSTIC_TEST:** Next-Gen Sequencing (NGS)

## Key facts

- **NCT ID:** NCT04297891
- **Lead sponsor:** Dr. Rebecca Schule
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-09-01
- **Primary completion:** 2024-06
- **Final completion:** 2025-06
- **Target enrollment:** 250 (ESTIMATED)
- **Last updated:** 2022-05-18

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04297891

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04297891, "Phenotypes, Biomarkers and Pathophysiology in Spastic Ataxias". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04297891. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*